Technical Data
045197
Rapamycin (Sirolimus, Rapamune, NSC 226080, Antibiotic AY-22989, WY-090217, RAPA, SILA 9268A, CCRIS 9024)
100ug
Biochemicals Storage: 4C/-20CShipping: Blue Ice
Antibiotic. Antibacterial and antifungal properties. Forms a complex with FKBP12 and inhibits the molecular target of rapamycin (mTOR). Inhibits the response to interleukin-2 (IL-2), and thereby blocks activation of T and B cells. Potent immunosuppressant used as an alternative to calcineurin inhibitors. Restricts the proliferation of smooth-muscle cells by blocking cell cycle progression at the G1/S transition. Anti-proliferative. Antitumor compound. Apoptosis enhancer. Activator of autophagy both in vitro and in vivo. Anti-HIV and anti-aging compound. Neuroprotective.

Storage and Stability:
Short-term Storage: +4C
Long-term Storage: -20C
Stable for at least 2 years after receipt when stored at -20C.

CAS Number:
53123-88-9

Molecular Formula:
C51H79NO13

Molecular Weight:
914.2
Purity: >98%

Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications without the expressed written authorization of United States Biological.
Product Reference:
Rapamycin (AY-22,989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active principle: C. Vezina, et al.; J. Antibiot. (Tokyo) 28, 721 (1975)
Rapamycin (AY-22,989), a new antifungal antibiotic. II. Fermentation, isolation and characterization: S.N. Sehgal, et al.; J. Antibiot. (Tokyo) 28, 727 (1975)
Inhibition of T and B lymphocyte proliferation by rapamycin: J.E. Kay, et al.; Immunology 72, 544 (1991)
FK506 and rapamycin: novel pharmacological probes of the immune response: J.Y. Chang, et al.; TIPS 12, 218 (1991) (Review)
Rapamycin-FKBP specifically blocks growth-dependent activation of and signaling by the 70 kd S6 protein kinases: J. Chung, et al.; Cell 69, 1227 (1992),
Rapamycin inhibition of interleukin-2-dependent p33cdk2 and p34cdc2 kinase activation in T lymphocytes: W.G. Morice, et al.; J. Biol. Chem. 268, 22737 (1993)
A mammalian protein targeted by G1-arresting rapamycin-receptor complex: E.J. Brown, et al.; Nature 369, 756 (1994)
Rapamycin, a potent immunosuppressive drug, causes programmed cell death in B lymphoma cells: S. Muthukkumar, et al.; Transplantation 60, 264 (1995)
Rapamycin enhances apoptosis and increases sensitivity to cisplatin in vitro: Y. Shi, et al.; Cancer Res. 55, 1982 (1995)
Mechanism of action of the immunosuppressant rapamycin: F.J. Dumont & Q. Su; Life Sci. 58, 373 (1996) (Review)
Rapamycin causes poorly reversible inhibition of mTOR and induces p53- independent apoptosis in human rhabdomyosarcoma cells: H. Hosoi, et al.; Cancer Res. 59, 886 (1999)
Rapamycin in transplantation: a review of the evidence: R.N. Saunders, et al.; Kidney Int. 59, 3 (2001) (Review)
Rapamycin in cardiovascular medicine: P.N. Ruygrok, et al.; Intern. Med. J. 33, 103 (2003) (Review)
Rapamycin: an anti-cancer immunosuppressant?: B.K. Law; Crit. Rev. Oncol. Hematol. 56, 47 (2005) (Review)
Tubers and tumors: rapamycin therapy for benign and malignant tumors: D.R. Plas & G. Thomas; Curr. Opin. Cell Biol. 21, 230 (2009) (Review)
Potential use of rapamycin in HIV infection: M. Donia, et al.; Br. J. Clin. Pharmacol. 70, 784 (2010) (Review)
Resveratrol and rapamycin: are they anti-aging drugs? M. Kaeberlein; Bioessays 32, 96 (2010)
Fighting neurodegeneration with rapamycin: mechanistic insights: J. Bov, et al.; Nat. Rev. Neurosci. 12, 437 (2011) (Review)


Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.